Table 1.
Characteristics by antidepressant group
| Paroxetine (n=630) | Fluoxetine (n=253) | Sertraline (n=541) | Fluvoxamine (n=174) | Citalopram (n=467) | Venlafaxine (n=365) | |
|---|---|---|---|---|---|---|
| Age (years)* | ||||||
| 66-70 | 55 (8.7) | 35 (13.8) | 37(6.8) | 10 (5.8) | 32 (6.9) | 49 (13.4) |
| 71-75 | 159 (25.2) | 79 (31.2) | 119 (22.0) | 34 (19.5) | 118 (25.3) | 153 (41.9) |
| 76-80 | 181 (28.7) | 68 (26.9) | 153 (28.3) | 51 (29.3) | 125 (26.8) | 83 (22.7) |
| 81-85 | 124 (19.7) | 49 (19.4) | 110 (20.3) | 42 (24.1) | 106 (22.7) | 51 (14.0) |
| ≥86 | 111 (17.6) | 22 (8.7) | 122 (22.6) | 37 (21.3) | 86 (18.4) | 29 (8.0) |
| Tamoxifen started† | ||||||
| ≤365 days | 517 (82.1) | 184 (72.7) | 439 (81.2) | 142 (81.6) | 412 (88.2) | 331 (90.7) |
| >365 days | 113 (17.9) | 69 (27.3) | 102 (18.9) | 32 (18.4) | 55 (11.8) | 34 (9.3) |
| Drugs dispensed‡ | 12 (8 to 16) | 12 (8 to 16) | 12 (8 to 15) | 11 (7 to 17) | 12 (8 to16) | 10 (7 to15) |
| Income quintile§ | ||||||
| 1 (lowest) | 130 (20.6) | 58 (22.9) | 106 (19.6) | 35(20.1) | 109 (23.3) | 69 (18.9) |
| 2 | 138 (21.9) | 52 (20.6) | 131 (24.2) | 33 (19.0) | 92 (19.7) | 73 (20.0) |
| 3 | 143 (22.7) | 49 (19.4) | 99 (18.3) | 31 (17.8) | 87(18.6) | 69 (18.9) |
| 4 | 111 (17.6) | 43 (17.0) | 93 (17.2) | 38 (21.8) | 86 (18.4) | 81 (22.2) |
| 5 (highest) | 106 (16.8) | 49 (19.4) | 108 (20.0) | 32 (18.4) | 92 (19.7) | 71(19.5) |
| Missing | ** | ** | ** | ** | ** | ** |
| Year of diagnosis | ||||||
| 1964-73 | 7 (1.1) | ** | ** | ** | ** | ** |
| 1974-83 | 22 (3.5) | 23 (9.1) | 21 (3.9) | ** | 7 (1.5) | ** |
| 1984-92 | 50 (7.9) | 30 (11.9) | 50 (9.2) | 18 (10.3) | 20 (4.3) | 15 (4.1) |
| 1993-2005 | 551 (87.5) | 196 (77.5) | 465 (86.0) | 150 (86.2) | 435 (93.2) | 345 (94.5) |
| Tamoxifen duration|| | 4.2 (2.3-5.0) | 3.2 (1.4-4.8) | 3.9 (2.1-4.9) | 3.6 (1.7-5.0) | 4.2 (2.5-5.1) | 4.1 (2.5-4.9) |
*Frequency (%) by age group in the year before stopping tamoxifen by antidepressant group.
†Frequency (%) starting tamoxifen within a year or greater from breast cancer diagnosis by antidepressant group.
‡Median number of drugs (IQR) dispensed in the year before completion of tamoxifen treatment by antidepressant group.33
§Income quintiles used to estimate socioeconomic status by antidepressant group.
||Median duration of tamoxifen use in years (IQR) by antidepressant group.
**Cell sizes ≤5 are suppressed in accordance with institutional privacy policy.